MedPath

DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO

DOKTOR FALK FARMA GMBKH, PREDSTAVITELSTVO logo
🇷🇺Russia
Ownership
Private
Employees
101
Market Cap
-
Website
http://www.drfalkpharma.de

Clinical Trials

330

Active:274
Completed:37

Trial Phases

4 Phases

Phase 1:197
Phase 2:21
Phase 3:31
+1 more phases

Drug Approvals

18

NMPA:17
EMA:1

Drug Approvals

Ursodeoxycholic Acid Capsules

Product Name
优思弗
Approval Number
国药准字HJ20181059
Approval Date
Oct 11, 2024
NMPA

Mesalazine Enteric-coated Tablets

Product Name
莎尔福
Approval Number
国药准字HJ20171358
Approval Date
Sep 10, 2024
NMPA

Ursodeoxycholic Acid Oral Suspension

Product Name
熊去氧胆酸口服混悬液
Approval Number
国药准字HJ20240072
Approval Date
Jul 16, 2024
NMPA

Mesalazine Suppositories

Product Name
莎尔福
Approval Number
国药准字HJ20150314
Approval Date
Jul 5, 2024
NMPA

Mesalazine Suppositories

Product Name
莎尔福
Approval Number
国药准字HJ20140947
Approval Date
Jul 5, 2024
NMPA

Mesalazine Suppositories

Product Name
莎尔福
Approval Number
国药准字HJ20150280
Approval Date
Jul 5, 2024
NMPA

Mesalazine Enemas

Product Name
莎尔福
Approval Number
国药准字HJ20150127
Approval Date
Jul 5, 2024
NMPA

Mesalazine Suppositories

Product Name
莎尔福
Approval Number
国药准字HJ20140948
Approval Date
Jul 5, 2024
NMPA

Mesalazine Enteric-coated Tablets

Product Name
莎尔福
Approval Number
国药准字HJ20202002
Approval Date
Jul 28, 2020
NMPA

Ursodeoxycholic Acid Capsules

Product Name
优思弗
Approval Number
H20181059
Approval Date
May 21, 2020
NMPA
  • Prev
  • 1
  • 2
  • Next

Clinical Trials

Distribution across different clinical trial phases (250 trials with phase data)• Click on a phase to view related trials

Phase 1
197 (78.8%)
Phase 3
31 (12.4%)
Phase 2
21 (8.4%)
Phase 4
1 (0.4%)

Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)

Phase 3
Not yet recruiting
Conditions
Primary Sclerosing Cholangitis
Interventions
First Posted Date
2025-03-20
Last Posted Date
2025-03-20
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
120
Registration Number
NCT06886360

Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

Phase 3
Recruiting
Conditions
Eosinophilic Esophagitis
Interventions
First Posted Date
2024-09-19
Last Posted Date
2025-06-17
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
308
Registration Number
NCT06596252
Locations
🇺🇸

Dr. Falk Investigational Site, Harlingen, Texas, United States

🇪🇸

Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain

Different Doses of Naronapride Vs. Placebo in Gastroparesis

Phase 2
Recruiting
Conditions
Gastroparesis
Interventions
Drug: Placebo
First Posted Date
2022-11-18
Last Posted Date
2025-02-06
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
320
Registration Number
NCT05621811
Locations
🇺🇸

Dr Falk Investigational Site, Harlingen, Texas, United States

🇧🇪

University of Leuven, Leuven, Belgium

Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Phase 2
Completed
Conditions
Eosinophilic Esophagitis
Interventions
First Posted Date
2022-08-04
Last Posted Date
2023-09-07
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
5
Registration Number
NCT05488405
Locations
🇨🇭

Universitätsspital Zürich, Zürich, Switzerland

Different Doses of ZED1227 vs. Placebo in NAFLD

Phase 2
Completed
Conditions
NAFLD
Liver Fibrosis
Interventions
Drug: Placebo
First Posted Date
2022-03-31
Last Posted Date
2024-05-14
Lead Sponsor
Dr. Falk Pharma GmbH
Target Recruit Count
186
Registration Number
NCT05305599
Locations
🇩🇪

Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz, Mainz, Rheinland-Pfalz, Germany

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 8
  • Next

News

Breakthrough Therapies Set to Transform Eosinophilic Esophagitis Treatment Landscape

The eosinophilic esophagitis (EoE) market is projected to grow from $1.8 billion in 2023 to a significantly higher value by 2034, driven by increased disease awareness and healthcare spending.

© Copyright 2025. All Rights Reserved by MedPath